title: Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells.
abstract: The objectives of this study were to determine the protein binding and lipoprotein distribution of G3139 and G3139 lipoplexes following incubation in human plasma, assess complement activation of, and the effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma on in vitro cellular uptake of G3139. Effect of concentration and time on incorporation of free and lipid associated (lipoplexes) [3H]Bcl-2 AO (25-600 ng/ml) into normolipidemic human plasma lipoproteins was determined by density gradient ultracentrifugation after incubation at 37 degrees C for 5, 30, 60 and 120 min. Protein binding in the lipoprotein deficient fractions (LPDP) was determined by equilibrium dialysis. Complement interaction was determined by ELISA after exposure of human plasma to AO+/- liposomes prepared in serial dilution. In vitro uptake of G3139 and G3139 lipoplexes into human melanoma cells was assessed qualitatively by fluorescence microscopy after 4-h exposure to G3139 (free or as lipoplexes) with or without pre-incubation of G3139 in normal human plasma. Analysis of Bcl-2 AO-lipoprotein interaction over time and concentration indicated no significant movement of the compound within the different lipoprotein and LPDP fractions. Majority of drug was recovered within LPDP fraction, and more than 85% of drug recovered within LPDP fraction was protein bound. No significant activation of complement was noted for either free AO or lipoplexes. Pre-incubation of free AO or AO-lipoplexes in human plasma resulted in a greater cellular uptake of AO-lipoplexes compared with plasma free controls. These findings suggest that the majority of [3H]Bcl-2 AO is plasma protein bound with little lipoprotein association and no significant movement between different lipoprotein and LPDP fractions. Plasma protein binding other than lipoprotein binding may be responsible for the difference in cellular uptake of free AO vs. cationic lipoplexes.
authors.affiliation: Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada V6T 1Z3. kwasan@interchange.ubc.ca
authors.forename: Ellen K
authors.initials: EK
authors.lastname: Wasan
authors.forename: Dawn
authors.initials: D
authors.lastname: Waterhouse
authors.forename: Olena
authors.initials: O
authors.lastname: Sivak
authors.forename: Marcel B
authors.initials: MB
authors.lastname: Bally
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Klasa
authors.forename: Kishor M
authors.initials: KM
authors.lastname: Wasan
mesh_terms: D001798:Blood Proteins / Q000378:metabolism*; D003167:Complement Activation / Q000187:drug effects; D019254:Genes, bcl-2 / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D008055:Lipids; D008074:Lipoproteins / Q000378:metabolism*; D008545:Melanoma / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D011485:Protein Binding; D014407:Tumor Cells, Cultured
chemical_list: D001798:Blood Proteins; D008055:Lipids; D008074:Lipoproteins; D016376:Oligonucleotides, Antisense